how similar are the bioidentical HRT

The short version: bioidentical HRT products differ from each other and from conventional HRT in meaningful ways, but the evidence comparing them directly is thin and mostly funded by manufacturers.

The term "bioidentical" covers a range of products that use 17β-estradiol and natural progesterone, the same molecules your body makes. But how similar they are depends on the route, the dose, and the specific formulation. A transdermal patch, a gel, and an oral capsule all deliver the same molecule, but they produce very different blood levels and ratios of estradiol to estrone.

Oral estradiol goes through the liver first, which converts much of it to estrone. The evidence shows that oral estradiol produces an estradiol-to-estrone ratio around 1:5, while transdermal methods keep the ratio closer to 1:1, which is more like natural physiology [3, 4]. Transdermal delivery also avoids the first-pass liver effect, which lowers the risk of blood clots. The ESTHER study found that oral estrogen raised the risk of venous thromboembolism (VTE) about 10-fold, while transdermal estrogen raised it only about 3-fold [2]. The MEVE cohort study found that oral estrogen carried a 6.4-fold higher risk of recurrent VTE compared to transdermal [2].

Even within the same route, products are not interchangeable. A 1992 crossover study showed that three different transdermal estradiol regimens produced mean serum estradiol levels ranging from 41 to 103 pg/mL [3]. The estradiol gel studies showed that a 1.25 g dose produced 33.5 pg/mL while a 2.5 g dose produced 65.0 pg/mL [5]. These are not trivial differences.

The REPLENISH phase 3 trial tested a single-capsule combination of 17β-estradiol and natural progesterone at four dose levels, from 0.25 mg estradiol/50 mg progesterone up to 1.0 mg/100 mg [1]. That trial was funded by the manufacturer (TherapeuticsMD) and used surrogate endpoints (reduction in hot flash frequency and severity) rather than hard clinical outcomes like fractures, heart disease, or death. The endometrial safety endpoint was a biopsy finding, not a clinical event.

What the evidence does not cover is long-term safety comparisons between different bioidentical products. No trial has compared one bioidentical product against another for hard outcomes like breast cancer, cardiovascular events, or all-cause mortality over 10 or 20 years. The Women's Health Initiative, which found increased risks of breast cancer, stroke, and blood clots with conventional HRT, used conjugated equine estrogens and synthetic progestins, not bioidentical hormones. Whether bioidentical products carry different long-term risks is simply not known from the evidence here.

My call: bioidentical products are not all the same. The route of delivery matters more than the molecule itself. Transdermal products avoid the liver and produce a more natural hormone ratio, which likely lowers the clotting risk. But the evidence comparing different bioidentical products to each other for long-term outcomes is absent, and the trials that exist are manufacturer-funded and use surrogate endpoints. If you are considering HRT, the choice between oral and transdermal is the most important decision, and the specific product matters less than the route. Confidence: moderate for the route differences, low for product-to-product comparisons.